PO.MCB05.02 · 分子与细胞生物学

巴西三阴性乳腺癌患者中的种系HRR改变与祖源相关结局:一项全面的基因组和临床研究

Germline HRR alterations and ancestry-related outcomes in Brazilian triple-negative breast cancer patients: A comprehensive genomic and clinical study

海报缩略图:巴西三阴性乳腺癌患者中的种系HRR改变与祖源相关结局:一项全面的基因组和临床研究
编号 531 展板 22 时间 4/19 02:00–05:00 区域 Section 21 主讲 Dirce Carraro, PhD
分会场 Mechanisms and Targets in DNA Damage Repair
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Rafael C. Brianese1, Karina M. Santiago1, Gabriel Bandeira do Carmo1, Leticia S. Pimentel1, Diego Ortunes2, Rafaella Ormond2, Marcos L. Santoro2, Giovana T. Torrezan1, Marcelo Moreno3, Ândrea R. dos Santos4, Marina de Brot5, Fabiana B. A. Makdissi6, Solange M. Sanches7, Jose C. C. Rocha8, Dirce Maria Carraro1

1Clinical and Functional Genomics Group, A.C.Camargo Cancer Center, Sao Paulo, Brazil,2Department of Biochemistry, Federal University of São Paulo (UNIFESP), Sao Paulo, Brazil,3Medicine Course and Biomedical Sciences, Federal University of Fronteira Sul (UFFS), Chapeco, Brazil,4Laboratory of Human and Medical Genetics, Postgraduate Program of Genetics and Molecular Biology, In, Federal University of Pará (UFPA), Belem, Brazil,5Department of Anatomic Pathology, A.C.Camargo Cancer Center, Sao Paulo, Brazil,6Department of Breast Surgery, A.C.Camargo Cancer Center, Sao Paulo, Brazil,7Department of Medical Oncology, A.C.Camargo Cancer Center, Sao Paulo, Brazil,8Department of Oncogenetics, A.C.Camargo Cancer Center, Sao Paulo, Brazil

摘要 Abstract

中文摘要
三阴性乳腺癌(TNBC)是一种侵袭性强且异质性高的乳腺癌亚型,常与早发、非洲祖源以及种系致病变异(GPV)相关,尤其是BRCA1中的变异。同源重组修复(HRR)基因的功能缺失性种系突变最终导致同源重组缺陷(HRD),这是一种赋予对DNA损伤剂(如铂类化疗和PARP(聚ADP核糖聚合酶)抑制剂)易感性增加的分子表型。虽然这一机制在欧洲和北美队列中已得到充分表征,但在混合人群中的研究仍然有限。我们开展了一项对320例未经选择的巴西TNBC患者的全面回顾性研究,整合了多基因二代测序(NGS)panel、祖源分析以及临床病理数据。在多基因癌症易感panel上分析了种系变异,并使用Axiom Precision Medicine Diversity Array和ADMIXTURE(K=4)在248例患者中确定了祖源。在29.1%的患者中检测到GPV,其中BRCA1是最常发生改变的基因(14.7%),其次是BRCA2(4.4%)和非BRCA的HRR基因(4.7%)。总体而言,23.8%的患者携带HRR相关基因的GPV。BRCA1携带者诊断时明显更年轻,更可能出现双侧肿瘤,并且与非携带者相比表现出更好的3年无进展生存期(3y-PFS)(p = 0.0162)。其他HRR基因的携带者也具有更优的3y-PFS(p = 0.0398)。合并来看,HRR携带者表现出优于非携带者的3y-PFS(p = 0.0025)和5年总生存期(5y-OS,p = 0.0260)。祖源分析显示以欧洲祖源为主(87.1%),但也存在相当比例的非洲和美洲原住民成分(分别在68.5%和81.4%的患者中≥1%),证实了巴西复杂的混合特征。以非洲祖源为主的患者与以欧洲祖源为主的患者相比,3y-PFS(p = 0.0011)和5y-OS(p = 0.0117)显著更差。自我报告的种族仅与分子祖源部分相关。聚焦于BRCA1位点的局部祖源分析显示,25%的个体携带非洲来源的单倍型,但未发现BRCA1局部祖源与癌症类型之间存在显著关联(p > 0.05)。这是迄今为止在拉丁美洲人群中开展的最大规模的TNBC种系研究,独特地整合了遗传、临床和祖源数据。我们的发现强化了HRR基因(尤其是BRCA1)在TNBC易感性和预后中的核心作用,并揭示了值得进一步研究的祖源相关生存差异。对局部祖源成分的持续分析将为理解高度混合人群中TNBC的基因组和临床异质性提供更多见解。
查看英文原文 English abstract
Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous breast cancer subtype frequently associated with early-onset, African ancestry, and germline pathogenic variants (GPVs), particularly in BRCA1 . Loss of function germline mutation in homologous recombination repair (HRR) genes culminate in homologous recombination deficiency (HRD), a molecular phenotype that confers increased susceptibility to DNA-damaging agents such as platinum-based chemotherapy and PARP (poly ADP-ribose polymerase) inhibitors. While this mechanism is well-characterized in European and North American cohorts, studies in admixed populations remain limited. We conducted a comprehensive retrospective study of 320 unselected Brazilian TNBC patients, integrating multigene next-generation sequencing (NGS) panels, ancestry analysis, and clinical-pathological data. Germline variants were analyzed across cancer predisposition multi gene panels, and ancestry was determined in 248 patients using the Axiom Precision Medicine Diversity Array and ADMIXTURE (K=4). GPVs were detected in 29.1% of patients, with BRCA1 being the most frequently altered gene (14.7%), followed by BRCA2 (4.4%) and non- BRCA HRR genes (4.7%). Overall, 23.8% of patients harbored GPVs in HRR-related genes. BRCA1 carriers were significantly younger at diagnosis, more likely to present bilateral tumors, and showed improved 3-year progression-free survival (3y-PFS) compared to non-carriers (p = 0.0162). Carriers of other HRR genes also had superior 3y-PFS (p = 0.0398). Combined, HRR-carriers exhibited better 3y-PFS (p = 0.0025) and 5-year overall survival (5y-OS, p = 0.0260) than non-carriers. Ancestry analysis revealed a predominance of European ancestry (87.1%) but also substantial African and Native American components (≥1% in 68.5% and 81.4%, respectively), confirming Brazil's complex admixture. Patients with predominant African ancestry had significantly worse 3y-PFS (p = 0.0011) and 5y-OS (p = 0.0117) compared to those with European ancestry. Self-reported race only partially correlated with molecular ancestry. Local ancestry analysis focused on the BRCA1 locus showed that 25% of individuals carried African-derived haplotypes, but no significant associations were found between BRCA1 local ancestry and cancer type (p > 0.05). This is the largest TNBC germline study conducted in a Latin American population to date, uniquely integrating genetic, clinical, and ancestry data. Our findings reinforce the central role of HRR genes, particularly BRCA1 , in TNBC predisposition and prognosis, and reveal ancestry-related survival disparities that merit further investigation. Ongoing analyses of local ancestry components will provide additional insights into the genomic and clinical heterogeneity of TNBC in highly admixed populations.
利益披露 Disclosure
R. C. Brianese, None.. K. M. Santiago, None.. G. B. do Carmo, None.. L. S. Pimentel, None.. D. Ortunes, None.. R. Ormond, None.. M. L. Santoro, None.. G. T. Torrezan, None.. M. Moreno, None.. Â. R. dos Santos, None.. M. de Brot, None.. F. B. A. Makdissi, None.. S. M. Sanches, None.. J. C. C. Rocha, None.. D. M. Carraro, None.

← 返回 AACR 2026 检索